Figure 4.
Plasma FGF-19 levels prior to and following a 75 gram oral glucose load (ingested in portions over twenty minutes, marked by shaded area) in participants with PBH and neuroglycopenia. Participants received blinded infusion of either exendin-9–39 (black circles) or placebo (saline) (clear squares) in a crossover fashion. * p < 0.05, *** p <0.0001 for comparison of placebo vs. exendin 9–39. ANOVA for time, treatment and the interaction of time and treatment p < 0.001, p = 0.02 and p=0.0507, respectively.
